Detailed Study Background
EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes for EGFR-mutant NSCLC patients, but efficacy remains limited for those with brain metastases—a subgroup with particularly poor prognosis and high unmet needs. Asandeutertinib is a third-generation, high-selectivity, irreversible EGFR-TKI developed by TYK Medicines, designed to overcome these limitations, boasting a favorable safety and pharmacokinetic profile, especially in the central nervous system. Early-phase studies already suggested its superior intracranial efficacy and safety.
Study Design and Endpoints
- The pivotal ESAONA Phase II study was an open-label, multicenter, randomized trial enrolling 224 patients with classic EGFR mutations and brain metastases.
- Patients were randomized 1:1 to asandeutertinib (160mg QD) or osimertinib (80mg QD), stratified by mutation subtype and intracranial lesion count.
- Primary endpoints: Intracranial objective response rate (iORR) and intracranial progression-free survival (iPFS), both assessed by Blinded Independent Central Review (BICR).
- Secondary endpoints: Investigator-assessed iORR/iPFS, overall response rate (ORR), progression-free survival (PFS), intracranial duration of response (iDoR), overall survival (OS), and safety.
Key Results and Data
Intracranial Efficacy
- BICR-iORR: Asandeutertinib achieved a significantly higher confirmed intracranial objective response rate versus osimertinib (95.5% vs. 79.6%, between-group difference 15.62%, 95% CI: 6.66%-24.34%, P=0.0004).
- Superiority was consistent across all prespecified subgroups.
- Median BICR-iPFS: Not reached for asandeutertinib (95% CI: 22.4-NA) vs. 17.51 months for osimertinib (HR=0.46, 95% CI: 0.28-0.76, P=0.0020).
- 18-month iPFS rates: 75.24% (asandeutertinib) vs. 48.12% (osimertinib).
- 24-month iPFS rates: 61.56% (asandeutertinib) vs. 38.28% (osimertinib).
- Median iDoR (BICR): Not reached for asandeutertinib vs. 16.26 months for osimertinib (HR=0.50, P=0.0148).
- Investigator-assessed results were consistent, further supporting efficacy.
Systemic Efficacy
- BICR-ORR (systemic): 89.2% (asandeutertinib) vs. 77.9% (osimertinib), P=0.0301.
- Median PFS: Not reached for asandeutertinib vs. 17.22 months for osimertinib (HR=0.64, P=0.0473).
- OS data remain immature and follow-up is ongoing.
Safety Profile
- All patients in the asandeutertinib group and nearly all in the osimertinib group experienced at least one treatment-emergent adverse event (TEAE).
- Grade 3 or higher TEAEs: 49.5% (asandeutertinib) vs. 21.2% (osimertinib).
- Most serious adverse events were manageable with dose modification or symptomatic treatment.
- Permanent discontinuation due to treatment-related adverse events occurred in only four patients in each group.
Regulatory and Commercial Impact
- The New Drug Application (NDA) for asandeutertinib has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China and granted priority review status.
- Several additional studies of asandeutertinib (as monotherapy and in combination) are underway in China, targeting broader patient populations and indications.
Implications for Investors
- Significant price-sensitive news: The robust superiority of asandeutertinib over osimertinib in a high-need population, coupled with ongoing regulatory review and priority status in China, positions TYK Medicines for a potentially transformative commercial opportunity in the NSCLC market segment.
- If approved and commercialized, asandeutertinib could become a new standard-of-care for EGFR-mutant NSCLC patients with brain metastases, a subgroup with limited effective options.
- Investors should note that while iPFS/PFS and OS data are not mature, interim efficacy signals are compelling and may support rapid regulatory and market uptake if confirmed in final analyses.
- The company is still exposed to clinical and regulatory risk, and there is no assurance of ultimate approval or commercial success.
About TYK Medicines, Inc.
TYK Medicines is an international, innovation-driven biopharmaceutical company established in 2017, specializing in next-generation kinase inhibitors for cancer treatment. The company has developed over a dozen drug candidates across various clinical stages and is committed to delivering more effective and safer anti-tumor therapies.
Board and Leadership
As of the announcement date, Dr. WU Yusheng serves as Chairman, Executive Director, and CEO, supported by a board of experienced scientific and business leaders.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. There is no guarantee that TYK Medicines will successfully develop or commercialize asandeutertinib or any other product candidates. Investors should exercise caution and consult their own advisors before trading in the company’s shares.
【繁體中文】TYK Medicines公佈Asandeutertinib於EGFR突變NSCLC腦轉移首線治療關鍵性II期數據超越標桿藥物
重點摘要
- TYK Medicines於2026年ASCO年會口頭發佈asandeutertinib（TY-9591）關鍵II期臨床數據。
- 本研究比較asandeutertinib與現有標桿osimertinib作為EGFR突變非小細胞肺癌（NSCLC）腦轉移患者首線治療之表現。
- Asandeutertinib於腦內療效顯著超越osimertinib，系統性療效亦具潛力。
- asandeutertinib新藥上市申請（NDA）已獲中國國家藥監局藥審中心（CDE）受理並納入優先審評。
- 安全性可控，大部分不良事件經處理或劑量調整後緩解。
詳細研究背景
雖然EGFR TKI類藥物改善了EGFR突變NSCLC患者的預後，但對腦轉移患者療效有限。Asandeutertinib為TYK Medicines自主研發的第三代高選擇性EGFR-TKI，具獨特藥代動力學及良好中樞神經系統穿透性。早期臨床已證明其腦內療效優於現有藥物。
研究設計及終點
- ESAONA II期關鍵臨床為多中心、開放性、隨機對照研究，共納入224名經典EGFR突變且腦轉移的患者。
- 受試者1:1隨機分配至asandeutertinib（160mg QD）或osimertinib（80mg QD）組，並按突變類型及腦內病灶數量分層。
- 主要終點： 由盲法獨立中心評審（BICR）評定的腦內客觀緩解率（iORR）及無進展生存期（iPFS）。
- 次要終點： 調查者評價iORR/iPFS、總體緩解率（ORR）、無進展生存（PFS）、腦內緩解持續時間（iDoR）、總體生存（OS）及安全性。
主要數據及結果
腦內療效
- BICR-iORR： Asandeutertinib顯著高於osimertinib（95.5%對79.6%，組間差15.62%，P=0.0004）。
- 所有分層亞組均顯示一致優勢。
- 中位BICR-iPFS： asandeutertinib未達（95%CI: 22.4-NA），osimertinib為17.51月（HR=0.46，P=0.0020）。
- 18個月iPFS： 75.24%（asandeutertinib）對48.12%（osimertinib）。
- 24個月iPFS： 61.56%對38.28%。
- 腦內緩解持續時間未成熟，但asandeutertinib組明顯優於osimertinib。
- 調查者評價結果與BICR一致，支持療效穩健。
全身療效
- BICR-ORR（全身）： 89.2%（asandeutertinib）對77.9%（osimertinib），P=0.0301。
- 中位PFS： asandeutertinib未達，osimertinib為17.22月（HR=0.64，P=0.0473）。
- OS數據尚未成熟，隨訪仍在進行。
安全性
- Asandeutertinib組所有患者及osimertinib組99.1%患者出現至少一項治療相關不良事件。
- 三級或以上不良事件：asandeutertinib組49.5%，osimertinib組21.2%。
- 大多數嚴重不良事件經劑量調整或對症處理後可控。
- 因治療相關不良事件永久停藥者兩組均為4例。
監管及商業影響
- Asandeutertinib新藥上市申請已被中國NMPA藥審中心受理並納入優先審評，有望加速上市。
- 多項asandeutertinib單藥及聯合治療臨床研究正於中國展開，佈局更廣泛適應症。
投資者須知
- 極具價格敏感性消息： asandeutertinib於高需求人群中顯著優於現有標準，結合中國優先審評，有望成為公司改變性商業機會。
- 如獲批並商業化，有機會成為EGFR突變NSCLC腦轉移首線新標準。
- 需留意iPFS/PFS及OS數據尚未成熟，最終結論仍待後續數據證實。
- 公司仍面臨臨床及監管風險，無法保證最終獲批或商業成功。
公司簡介
TYK Medicines為國際創新生物醫藥公司，2017年成立，聚焦新一代激酶抑制劑，現有逾十項創新藥物處於不同臨床階段，致力提供更高效及安全腫瘤治療方案。
董事會團隊
公告日期董事會由吳宇生博士（主席、執行董事兼CEO）及多位醫藥領袖組成。
免責聲明
本文僅供資訊參考，並不構成投資建議。TYK Medicines能否最終成功開發及商業化asandeutertinib或其他候選藥物存在不確定性。投資者應審慎評估並諮詢專業顧問後作出投資決定。
